الفهرس Only 14 pages are availabe for public view
 |  | from | 72 |  |  |
| | | from | 72 | | |
Abstract
The last 40 years have seen major changes III the available health care teclmology. The development of antibiotics and antineoplastic dnlgS, advances in intensive care support, progress in itmntmomodulation, and the advent of organ transplantaion have all contributed to change the prognosis for degenerative diseases. Unforttmately, this prolonged survival of immunocompromised populations also makes them highly susceptible to invasive fungal infections (Beck-Sague, CM., E taL, 1993).Paralleling the increased prevalence of fimgal infections has been the introduction of new antifimgal agents and recognition of isolates resistant to antifungal dnlgs. The chronic use of azoles in the prophylaxis of systemic mycoses in bone marrow transplant patients and for long-term suppressive therapy in AIDS patients is a factor in the selection of isolates that are more resistant to azole therapy (Goodman, J.L., et a/., 1992)